Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.
A REIT's debt levels, interest rate issues and financial performance are important factors when deciding which DST with a 721 ...
The cost-effectiveness body had initially said that Ocrevus (ocrelizumab) was too expensive in primary progressive multiple sclerosis (PPMS) in first draft guidance issued last summer. In that ...
Medpage Today on MSN26d
How Progressive Multiple Sclerosis Differs From Relapsing-Remitting MSPPMS typically includes a steady loss of function from the onset of symptoms. The vast majority of people with MS receive ...
Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback